Ascendis Pharma (ASND) Company Report

Ascendis Pharma (ASND) reported Q3 2025 total revenue of €214 million, driven by Europad revenue of €143 million and Skytropha revenue of €50.7 million.
The company achieved a positive operating profit of €11 million in Q3 2025 and ended the quarter with €539 million in cash and cash equivalents.
TransCon CNP is in late-stage label discussions with the FDA, with a PDUFA date of November 30.
Europad's U.S. launch saw over 4,250 patients prescribed since launch to September, with more than 400 new patients in October alone.
Skytropha received its first label expansion with FDA approval for adult growth hormone deficiency in July.

Nov 12, 2025, 9:30 PM

Ascendis Pharma A/S Reports Q3 2025 Results with Significant Revenue Growth

ASND

Earnings

Product Launch

Revenue Acceleration/Inflection

Ascendis Pharma A/S reported revenue of €213,634 thousand for Q3 2025 and €472,632 thousand for the nine months ended September 30, 2025, representing a substantial increase primarily due to the launch of YORVIPATH in the U.S.
The company's net loss for the nine months ended September 30, 2025, improved to €(194,472) thousand from €(339,615) thousand in the prior year, and it achieved positive cash flows from operating activities for the first time in Q3 2025.
Key product developments include the commercial availability of YORVIPATH in Japan in November 2025 and its U.S. launch in late December 2024, alongside SKYTROFA's FDA approval for adults with growth hormone deficiency in July 2025 and its expanded U.S. commercial availability from October 22, 2025.
As of September 30, 2025, Ascendis Pharma A/S held €539.1 million in cash and cash equivalents and anticipates these resources will cover projected cash requirements for at least twelve months.

Nov 12, 2025, 9:15 PM

Ascendis Pharma A/S Reports Q3 2025 Financial Results and Pipeline Progress

ASND

Earnings

Product Launch

Revenue Acceleration/Inflection

Ascendis Pharma A/S reported total revenue of €213.6 million for the third quarter of 2025, with YORVIPATH® revenue totaling €143.1 million and SKYTROFA® revenue totaling €50.7 million.
The company achieved an operating profit of €11.0 million for Q3 2025, and a net loss of €61.0 million, or €1.00 per share.
As of September 30, 2025, Ascendis Pharma A/S held cash and cash equivalents of €539 million.
The New Drug Application (NDA) for TransCon® CNP (navepegritide) for the treatment of children with achondroplasia is under FDA Priority Review, with a PDUFA goal date of November 30, 2025. Additionally, the FDA approved the first label expansion for SKYTROFA® in adult growth hormone deficiency.

Nov 12, 2025, 9:05 PM

Ascendis Pharma A/S Submits MAA for TransCon CNP to EMA

ASND

Product Launch

On October 8, 2025, Ascendis Pharma A/S announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA).
The MAA is for TransCon CNP (navepegritide), an investigational prodrug.
TransCon CNP is intended as a treatment for children with achondroplasia, a rare genetic condition.
The drug is designed to provide continuous inhibition of the overactive FGFR3 pathway.

Oct 8, 2025, 8:13 PM

Ascendis Pharma Discusses Product Launches and Financial Independence at Wells Fargo Healthcare Conference

ASND

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

Ascendis Pharma is experiencing increasing revenue generation and expects to achieve positive cash contribution quarter by quarter, aiming for financial independence.
The company's YORVIPATH launch is performing well, with a $5 billion potential peak sales target for hypoparathyroidism and strong IP protection until 2042.
Ascendis Pharma anticipates FDA PDUFA for TransCon CNP by the end of November, highlighting its differentiation through continuous exposure and clinical benefits beyond linear growth.
The company plans to expand its pipeline, leveraging its TransCon technology for new compounds and potential out-licensing opportunities in large indications like cardiovascular diseases.

Sep 3, 2025, 1:04 PM

Earnings Transcripts

Quarterly earnings call transcripts for Ascendis Pharma.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop